Last reviewed · How we verify
Trifluridine and Tipiracil Hydrochloride (trifluridine-and-tipiracil-hydrochloride)
Trifluridine and Tipiracil Hydrochloride (generic name: trifluridine-and-tipiracil-hydrochloride) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
Trifluridine and tipiracil hydrochloride inhibit thymidylate synthase and DNA synthesis, leading to cell death in cancer cells.
At a glance
| Generic name | trifluridine-and-tipiracil-hydrochloride |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
This drug combination works by blocking an enzyme called thymidylate synthase, which is crucial for DNA replication. By inhibiting this enzyme, the drug prevents cancer cells from dividing and growing.
Approved indications
Common side effects
- Fatigue
- Nausea
- Hypertension
- Diarrhoea
- Proteinuria
- Platelet count decreased
- Vomiting
- Neutrophil count decreased
- Hypothyroidism
- Decreased appetite
- Abdominal pain
- Constipation
Key clinical trials
- Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans (NA)
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (PHASE1)
- TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (PHASE2)
- Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (PHASE3)
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer (PHASE2)
- Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (PHASE3)
- SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (PHASE2)
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trifluridine and Tipiracil Hydrochloride CI brief — competitive landscape report
- Trifluridine and Tipiracil Hydrochloride updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Trifluridine and Tipiracil Hydrochloride
What is Trifluridine and Tipiracil Hydrochloride?
How does Trifluridine and Tipiracil Hydrochloride work?
Who makes Trifluridine and Tipiracil Hydrochloride?
What is the generic name of Trifluridine and Tipiracil Hydrochloride?
What development phase is Trifluridine and Tipiracil Hydrochloride in?
What are the side effects of Trifluridine and Tipiracil Hydrochloride?
Related
- Manufacturer: Pfizer Inc. — full pipeline